ArticleFrontiers in cellular and infection microbiology2026
Tacrolimus inhibits CVB3-targeted regulation of TFEB by PPP3/calcineurin.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence indicates that Coxsackievirus B3 (CVB3) infection, a common cause of viral myocarditis, triggers the nuclear translocation of transcription factor EB (TFEB) through a mechanism dependent on the serine/threonine phosphatase Protein Phosphatase 3 (PPP3)/calcineurin, independent of its cleavage. Tacrolimus (TAC), a calcineurin inhibitor widely used in immunosuppressive therapy for cardiovascular conditions such as myocarditis and post-transplant vasculopathy, may modulate TFEB activity in this context. This study investigated the effect of TAC on TFEB regulation during CVB3 infection in HeLa cells. Our results demonstrate that TAC significantly suppresses both the nuclear accumulation and transcriptional activity of TFEB. Conversely, knockdown of Protein Phosphatase 3 Catalytic Subunit (PPP3C) enhances TFEB protein expression and its nuclear localization, indicating that TAC calcineurin-dependent mechanism beyond simple enzymatic inhibition. Moreover, TAC similarly inhibits the nuclear expression and transcriptional activity of both Δ60-TFEB (a cleavage fragment lacking the first 60 amino acids) and TFEBQS60LP (cleavage-resistant mutant). Knockdown of PPP3C leads to increased nuclear distribution of these TFEB variants, confirming that TAC targets PPP3/calcineurin to regulate TFEB and its modified forms. These findings suggest that TAC interferes with the CVB3-induced activation of TFEB, thereby influencing cellular autophagy and viral replication. Importantly, TAC treatment attenuates CVB3-induced autophagic response and reduces viral protein expression and RNA levels in infected cells. Collectively, this study reveals a novel role for TAC in modulating TFEB subcellular localization and activity in the context of CVB3 infection, with potential implications for the pharmacological management of viral myocarditis and associated cardiovascular pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.